The placebo effect was clearly demonstrated in
one of the earliest studies of anabolic steroids. Fifteen male athletes who had
been involved in heavy weightlifting for the previous two years volunteered for
a weight training experiment using anabolic steroids. They were told that those
who made the greatest strength gains over a preliminary four-month weight
training period would be selected for the second phase of the study, in which
they would receive anabolic steroids.
Following the initial period, 8 of these 15
subjects were randomly selected to enter the treatment phase. Only six of these
subjects passed all medical screening tests and were allowed to continue to the
treatment phase. This phase consisted of a four-week period in which the
subjects were told that they would receive 10 mg per day of Dianabol(an
anabolic steroid), when in fact they received a placebo – an inactive substance typically provided in a form identical
to the genuine drug.
Strength data were collected over the last
seven weeks of the four-month pretreatment training period and over all four
weeks of the treatment(placebo) period. Even through the subjects were
experienced weightlifters, they continued to gain impressive amounts of
strength during the pretreatment training period. However, strength gains while
subjects were taking the placebo were substantially greater than during the
pretreatment period! The group improved an average of 11kg(24lb) during the
seven-week pretreatment period but improved 45kg(~100lb) during the four-week
treatment(placebo) period. This represents an average gain in strength of
1.6kg(3.5lb) per week during the pretreatment training period and 11.3kg(25lb)
per week during the placebo period – a more than seven times greater increase
in the rate of strength gain during the placebo(supposed steroid) period over
the pretreatment training period. Furthermore, placebos are inexpensive, risk
free, and legal for use in sport.
One of the coaches repeatedly witnessed the
placebo effect while conducting a large series of studies investigating the
effects of beta-blocking drugs on the ability to perform single bouts of
exercise or to train aerobically. The Human Subjects Committee, a committee
mandated by the federal government to oversee all research conducted with human
subjects in the United States, requires that all human subjects receive a full
disclosure of the risks associated with any experimental intervention so that
they can provide informed consent before participating. Before the start of
each study, a cardiologist presented a comprehensive background of
beta-blocking drugs to each subject, including the drugs’ significance in
treating various cardiovascular diseases and potential side effects associated
with their use. It was amazing to note that over the course of six years of
study, the most serious side effects almost always appeared in the subjects
when taking the placebo.
When evaluating a substance for possible ergogenic
qualities, researchers must remember that witnessing and ergogenic effect does
not necessarily prove that a substance is truly ergogenic. All studies of
potential ergogenic substances must include a placebo group so that researchers
can compare actual responses resulting from the test substance with those
resulting from a placebo. In many studies, a double-blind experimental design
is used, in which neither the subject nor the experimenter knows who is getting
the proposed ergogenic aid and who is getting the placebo. This is done to
eliminate “experimenter bias”, whereby the experimenter’s beliefs might affect
the outcome of the study. With this design, the substances are coded and only
an independent person not associated with the project has access to the codes.
See the introductory chapter for more information on the proper control of
experiments.
0 коментара:
Постави коментар